Physician profile
Michael K Maley
NPI 1598742736
$3,010.59
in general payments reported to CMS, 2019-2025
22 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $192 · 2021: $160 · 2022: $235 · 2023: $685 · 2024: $370 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.49 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $381.71 | 2023-2024 | Envista Mx60 Iol, Amvisc, Toric |
| Abbvie INC. | $354.09 | 2022-2025 | |
| Allergan, INC. | $296.05 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $282.36 | 2020-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $217.22 | 2019-2021 | |
| Alcon Vision LLC | $205.13 | 2022-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Dompe US, INC. | $194.55 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $170.63 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $113.60 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $111.86 | 2021-2024 | Tecnis Iol |
| Harrow Eye, LLC | $106.92 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $106.80 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $77.66 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $71.66 | 2019-2020 | |
| Amgen INC. | $65.93 | 2024-2025 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $59.91 | 2022-2024 | Dextenza |
| Oyster Point Pharma, INC. | $56.47 | 2022-2025 | Tyrvaya |
| Shire North American Group INC | $55.60 | 2019 | |
| Glaukos Corporation | $28.74 | 2025 | Idosetr, Istent Infinite |
| Eyevance Pharmaceuticals LLC | $25.00 | 2019 | |
| Travere Therapeutics, INC. | $14.76 | 2021 | |
| Horizon Therapeutics Plc | $13.94 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.